首页> 外文会议>Photochemotherapy: Photodynamic Therapy and Other Modalities >Photodegradation of sensitizers in mouse skin during PCT
【24h】

Photodegradation of sensitizers in mouse skin during PCT

机译:PCT期间小鼠皮肤中光敏剂的光降解

获取原文
获取外文期刊封面目录资料

摘要

Abstract: All photosensitizers applied in experimental and clinical photochemotherapy (PCT) of cancer are degraded during light exposure. Under certain conditions this may be a disadvantage since larger light fluences are needed to destroy the malignant tissue. However, photodegradation may also offer an advantage: if the applied dose of sensitizer is so low that most of it is photodegraded before normal tissue is destroyed, but still large enough to sensitize the tumor to destruction, one may achieve a larger tumor to normal tissue therapeutic ratio than when using a higher dose of sensitizer. Tumors usually contain two to ten times higher concentrations of sensitizers than do the surrounding normal tissues. We have studied the photodegradation of a number of sensitizers, including Photofrin (PII), benzoporphyrin derivative mono acid ring A (BPD), chlorin e$-6$/ (Chle$-6$/) 5-aminolevulinic acid (ALA)- induced protoporphyrin IX (PpIX), meso-tetrahydroxyphenyl-chlorin (m-THPC), meso- tetrahydroxyphenyl-porphyrin (m-THPP) tetraphenylporphine tetrasulfonated (TPPS$-4$/), aluminum phthalocyanine disulfonated (AlPcS$-2$/), tetrasulfonated (AlPcS$-4$/) and zinc phthalocyanine (ZnPc) in liposomes. The sensitizers were injected in Balb/c nude mice and exposed to light from an argon pumped dye laser, tuned to the appropriate therapeutic wavelength at a fluence rate of 100 mW/cm$+2$/. The sensitizer fluorescence in the laser- exposed skin was monitored by a fiberoptic probe coupled to a fluorescence spectrometer. The kinetics of the fluorescence decay during PCT were, in all cases, nonexponential but differed from dye to dye. Chle$-6$/ and m-THPC were found to be the most photolabile sensitizers. AlPcS$-4$/ and AlPcS$-2$/ and, to a minor degree, TPPS$-4$/ showed a peculiar fluorescence increase during PCT, similar to what we have found earlier for these sensitizers in cells in vitro. The fluorescence increase is indicative of lysosomal localization and perforation of the lysosomes during PCT. !15
机译:摘要:在光的照射过程中,所有用于癌症的实验和临床光化学疗法(PCT)的光敏剂均会降解。在某些情况下,这可能是不利的,因为需要更大的光通量才能破坏恶性组织。但是,光降解也可能提供一个优势:如果敏化剂的剂量太低,以至于大多数光敏剂在正常组织被破坏之前就已被光降解,但仍然足够大,可以使肿瘤对破坏敏感,那么对正常组织可能会产生更大的肿瘤与使用更高剂量的敏化剂相比,治疗率更高。肿瘤通常含有比周围正常组织高两倍至十倍的敏化剂浓度。我们研究了许多光敏剂的光降解,包括光敏蛋白(PII),苯并卟啉衍生物单酸环A(BPD),二氢卟酚e $ -6 $ /(Chle $ -6 $ /)5-氨基乙酰丙酸(ALA)-诱导的原卟啉IX(PpIX),中四羟基苯基二氢卟酚(m-THPC),中四羟基苯基卟啉(m-THPP)四苯基卟啉四磺化(TPPS $ -4 $ /),酞菁铝二磺化(AlPcS $ -2 $ /) ,脂质体中的四磺化(AlPcS $ -4 $ /)和酞菁锌(ZnPc)。将敏化剂注射到Balb / c裸鼠中,并暴露于来自氩泵浦染料激光器的光,以100mW / cm 2 +2的通量率调谐至合适的治疗波长。激光暴露的皮肤中的敏化剂荧光是通过与荧光光谱仪耦合的光纤探针进行监测的。在所有情况下,PCT期间荧光衰减的动力学都是非指数的,但每种染料不同。 Chle $ -6 $ /和m-THPC被认为是最不光敏的敏化剂。 AlPcS $ -4 $ /和AlPcS $ -2 $ /以及较小程度的TPPS $ -4 $ /在PCT期间显示出独特的荧光增加,类似于我们先前在体外细胞中发现的这些敏化剂。荧光增加表明在PCT期间溶酶体的定位和溶酶体的穿孔。 !15

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号